Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review

Brain metastasis from intrahepatic cholangiocarcinoma (iCCA) is extremely rare, and no standard therapeutic strategy has been established. Camrelizumab is a programmed cell death protein 1 (PD-1) inhibitor that has been widely studied in treating liver cancer. Combined immunotherapy and targeted the...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Peiyi, Guo, Lei, Zhang, Bo, Xu, Yongfeng, Song, Qi, Shi, Hongcheng, Ye, Qinghai, Li, Hui, Xiao, Yongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382583/
https://www.ncbi.nlm.nih.gov/pubmed/35992782
http://dx.doi.org/10.3389/fonc.2022.911202
_version_ 1784769313107869696
author Xie, Peiyi
Guo, Lei
Zhang, Bo
Xu, Yongfeng
Song, Qi
Shi, Hongcheng
Ye, Qinghai
Li, Hui
Xiao, Yongsheng
author_facet Xie, Peiyi
Guo, Lei
Zhang, Bo
Xu, Yongfeng
Song, Qi
Shi, Hongcheng
Ye, Qinghai
Li, Hui
Xiao, Yongsheng
author_sort Xie, Peiyi
collection PubMed
description Brain metastasis from intrahepatic cholangiocarcinoma (iCCA) is extremely rare, and no standard therapeutic strategy has been established. Camrelizumab is a programmed cell death protein 1 (PD-1) inhibitor that has been widely studied in treating liver cancer. Combined immunotherapy and targeted therapy are a promising approach for treating advanced iCCA. Despite that immune checkpoint inhibitor (ICI)-based neoadjuvant therapy on iCCA has shown a significant response rate and resection rate, few reports have shown the therapeutic efficacy of immunotherapy in treating brain metastasis from iCCA. Although PD-1 inhibitors such as pembrolizumab, nivolumab, or camrelizumab are increasingly applied in clinic practice to treat multiple malignancies, to the best of our knowledge, we report the first case of an iCCA patient with brain metastasis successfully treated with a combined immunotherapy and targeted therapy. The patient is a 54-year-old man with metastatic iCCA in brain treated though camrelizumab plus lenvatinib therapy with a complete response (CR). By the time of writing, he has had a progression-free survival of 17.5 months and did not experience any severe side effects related to this therapy. Camrelizumab plus lenvatinib therapy showed favorable efficacy and manageable toxicity for this patient with advanced iCCA and could be of interest for more prospective randomized trials to further verify the potential clinical benefits.
format Online
Article
Text
id pubmed-9382583
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93825832022-08-18 Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review Xie, Peiyi Guo, Lei Zhang, Bo Xu, Yongfeng Song, Qi Shi, Hongcheng Ye, Qinghai Li, Hui Xiao, Yongsheng Front Oncol Oncology Brain metastasis from intrahepatic cholangiocarcinoma (iCCA) is extremely rare, and no standard therapeutic strategy has been established. Camrelizumab is a programmed cell death protein 1 (PD-1) inhibitor that has been widely studied in treating liver cancer. Combined immunotherapy and targeted therapy are a promising approach for treating advanced iCCA. Despite that immune checkpoint inhibitor (ICI)-based neoadjuvant therapy on iCCA has shown a significant response rate and resection rate, few reports have shown the therapeutic efficacy of immunotherapy in treating brain metastasis from iCCA. Although PD-1 inhibitors such as pembrolizumab, nivolumab, or camrelizumab are increasingly applied in clinic practice to treat multiple malignancies, to the best of our knowledge, we report the first case of an iCCA patient with brain metastasis successfully treated with a combined immunotherapy and targeted therapy. The patient is a 54-year-old man with metastatic iCCA in brain treated though camrelizumab plus lenvatinib therapy with a complete response (CR). By the time of writing, he has had a progression-free survival of 17.5 months and did not experience any severe side effects related to this therapy. Camrelizumab plus lenvatinib therapy showed favorable efficacy and manageable toxicity for this patient with advanced iCCA and could be of interest for more prospective randomized trials to further verify the potential clinical benefits. Frontiers Media S.A. 2022-08-03 /pmc/articles/PMC9382583/ /pubmed/35992782 http://dx.doi.org/10.3389/fonc.2022.911202 Text en Copyright © 2022 Xie, Guo, Zhang, Xu, Song, Shi, Ye, Li and Xiao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xie, Peiyi
Guo, Lei
Zhang, Bo
Xu, Yongfeng
Song, Qi
Shi, Hongcheng
Ye, Qinghai
Li, Hui
Xiao, Yongsheng
Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review
title Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review
title_full Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review
title_fullStr Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review
title_full_unstemmed Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review
title_short Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review
title_sort case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9382583/
https://www.ncbi.nlm.nih.gov/pubmed/35992782
http://dx.doi.org/10.3389/fonc.2022.911202
work_keys_str_mv AT xiepeiyi casereportimmunotherapysuccessfullytreatedbrainmetastasisinintrahepaticcholangiocarcinomaandliteraturereview
AT guolei casereportimmunotherapysuccessfullytreatedbrainmetastasisinintrahepaticcholangiocarcinomaandliteraturereview
AT zhangbo casereportimmunotherapysuccessfullytreatedbrainmetastasisinintrahepaticcholangiocarcinomaandliteraturereview
AT xuyongfeng casereportimmunotherapysuccessfullytreatedbrainmetastasisinintrahepaticcholangiocarcinomaandliteraturereview
AT songqi casereportimmunotherapysuccessfullytreatedbrainmetastasisinintrahepaticcholangiocarcinomaandliteraturereview
AT shihongcheng casereportimmunotherapysuccessfullytreatedbrainmetastasisinintrahepaticcholangiocarcinomaandliteraturereview
AT yeqinghai casereportimmunotherapysuccessfullytreatedbrainmetastasisinintrahepaticcholangiocarcinomaandliteraturereview
AT lihui casereportimmunotherapysuccessfullytreatedbrainmetastasisinintrahepaticcholangiocarcinomaandliteraturereview
AT xiaoyongsheng casereportimmunotherapysuccessfullytreatedbrainmetastasisinintrahepaticcholangiocarcinomaandliteraturereview